Trial Profile

A Phase 1b/2, Open-Label, Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 13 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Tivozanib (Primary)
Indications Liver cancer
Focus Adverse reactions
Acronyms DEDUCTIVE
Sponsors AVEO Oncology

Most Recent Events

10 Jul 2023 Status changed from active, no longer recruiting to discontinued.
21 Jan 2023 The protocol was amended in 2021 to include a cohort of patients previously treated with atezolizumab and bevacizumab (cohort B).
21 Jan 2023 Results presented at the 2023 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com